Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s74. https://doi.org/10.25251/skin.6.supp.74